Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7365-7374

  Chaston, Timothy B ^a   Watts, Ralph N ^a   Yuan, Jun ^a   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BENZOIC ACID; CATALASE; DEFEROXAMINE; DI 2 PYRIDYLKETONE 3 BROMOBENZOYLHYDRAZONE; DI 2 PYRIDYLKETONE 4 AMINOBENZOYLHYDRAZONE; DI 2 PYRIDYLKETONE 4 HYDROXYBENZOYLHYDRAZONE; DI 2 PYRIDYLKETONE BENZOYLHYDRAZONE; DI 2 PYRIDYLKETONE ISONICOTINOYLHYDRAZONE; DI 2 PYRIDYLKETONE THIOPHENECARBOXYLHYDRAZONE; DNA TOPOISOMERASE; EBSELEN; EDETIC ACID; FREE RADICAL; HYDRAZONE DERIVATIVE; HYDROGEN PEROXIDE; IRON CHELATING AGENT; PLASMID DNA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHELATION; CONTROLLED STUDY; DNA DAMAGE; DRUG DNA BINDING; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; FENTON REACTION; HUMAN; HUMAN CELL; IRON CHELATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; AZOLES; CATALASE; CELL LINE, TUMOR; CHELATING AGENTS; COLORING AGENTS; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; HUMANS; HYDRAZONES; HYDROGEN PEROXIDE; IRON; LIGANDS; MODELS, CHEMICAL; ORGANOSELENIUM COMPOUNDS; OXIDATION-REDUCTION; OXYGEN; PLASMIDS; PYRIDINES; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 8444235919     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0865     Document Type: Article

References (41)

1. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem 2003;10:1021-34.
2. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-30.
3. Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003;10:1035-49.
4. Donfrancesco A, Deb G, De Sio L, Cozza R, Castellano A. Role of deferoxamine in tumor therapy. Acta Haematol 1996;95:66-9.
5. Becton DL, Roberts B. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res 1989;49:4809-12.
6. Li J, Zheng LM, King I, Doyle TW, Chen SH. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr Med Chem 2001;8:121-33.
7. Cory JG, Cory AH, Rappa G, et al. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 1995;35:55-68.
8. Singh S, Khodr H, Taylor MI, Hider RC. Therapeutic iron chelators and their potential side effects. Biochem Soc Symp 1995;61:127-37.
9. Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 2001;7:3574-9.
10. Lovejoy DB, Richardson DR. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002;100:666-76.
11. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979;48:133-58.
12. Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91.
13. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9:402-14.
14. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-306.
15. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 1999;134:510-21.
16. Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol 2003;138:819-30.
17. Chaston TB, Richardson DR. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease. J Biol Inorg Chem 2003;8:427-38.
18. Richardson DR, Neumannova V, Nagy E, Ponka P. Effects of nitrogen monoxide species on cellular proliferation and transferrin and iron uptake by erythroleukemia (K562) cells. Blood 1995;86:3211-9.
19. Dean RT, Nicholson P. The action of nine chelators on iron-dependent radical damage. Free Radic Res 1994;20:83-101.
20. Gutteridge JM. Superoxide-dependent formation of hydroxyl radicals from ferric-complexes and hydrogen peroxide: an evaluation of fourteen iron chelators. Free Radic Res Commun 1990;9:119-25.
21. Hermes-Lima M, Nagy E, Ponka P, Schulman HM. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks. Free Radic Biol Med 1998;25:875-80.
22. Bernhardt PV, Caldwell LM, Chaston TB, Chin P, Richardson DR. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridylketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem 2003;8:866-80.
23. Jin L, Yang P. Synthesis and DNA binding studies of cobalt (III) mixed-polypyridyl complex. J Inorg Biochem 1997;68:79-83.
24. Kostoryz EL, Yourtee DM. Oxidative mutagenesis of doxorubicin-Fe(III) complex. Mutat Res 2001;490:131-9.
25. Kellogg GE, Scarsdale JN, Fornari FA Jr. Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides. Nucleic Acids Res 1998;26:4721-32.
26. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
27. Olive PL. DNA precipitation assay: a rapid and simple method for detecting DNA damage in mammalian cells. Environ Mol Mutagen 1988;11:487-95.
28. Wang MX, Wei A, Yuan J, Trickett A, Knoops B, Murrell GA. Expression and regulation of peroxiredoxin 5 in human osteoarthritis. FEBS Lett 2002;531:359-62.
29. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective anti-tumor activity: in vitro and in vivo assessment. Blood 2004;104:1450-8.
30. Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem 1999;4:266-73.
31. Trommel JS, Marzilli LG. Synthesis and DNA binding of novel water-soluble cationic methylcobalt porphyrins. Inorg Chem 2001;40:4374-83.
32. Kasahara K, Fujiwara Y, Sugimoto Y, et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst (Bethesda) 1992;84:113-8.
33. Kwok JC, Richardson DR. Anthracyclines induce accumulation of ferritin iron in normal and neoplastic cells: inhibition of the ferritin Fe mobilization pathway. Mol Pharmacol 2003;63:849-61.
34. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 1999;368:421-8.
35. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781-92.
36. Richardson DR. The therapeutic potential of iron chelators. Exp Opin Investig Drugs 1999;8:2141-58.
37. Mello Filho AC, Meneghini R. In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochim Biophys Acta 1984;781:56-63.
38. Aruoma OI, Halliwell B, Dizdaroglu M. Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. J Biol Chem 1989;264:13024-8.
39. Bodley A, Liu LF, Israel M, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989;49:5969-78.
40. Armstrong CM, Bernhardt PV, Chin P, Richardson DR. Structural variations and formation constants of first row transition metal complexes of biologically active aroylhydrazones. Eur J Inorg Chem 2003;1145-56.
41. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992;15:492-501.